Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

@inproceedings{Svensson2015RifampicinAR,
  title={Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug},
  author={Elin M Svensson and Stephen Murray and Mats O. Karlsson and Kelly E Dooley},
  booktitle={The Journal of antimicrobial chemotherapy},
  year={2015}
}
OBJECTIVES Bedaquiline is the first drug of a new class approved for the treatment of TB in decades. Bedaquiline is metabolized by cytochrome P450 (CYP) 3A4 to a less-active M2 metabolite. Its terminal half-life is extremely long (5-6 months), complicating evaluations of drug-drug interactions. Rifampicin and rifapentine, two anti-TB drugs now being optimized to shorten TB treatment duration, are potent inducers of CYP3A4. This analysis aimed to predict the effect of repeated doses of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS